AbbVie Inc (XBUL:4AB) Stock Price, Trades & News

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.13
Equity-to-Asset	-0.05
Debt-to-Equity	-10.95
Debt-to-EBITDA	4.31
Interest Coverage	7.16
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.3	Distress Grey Safe
Beneish M-Score	-2.68	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	1.8
	3-Year EBITDA Growth Rate	-9.9
	3-Year EPS without NRI Growth Rate	-10.1
	3-Year FCF Growth Rate	-9.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	21.13
	Future 3-5Y Total Revenue Growth Rate Estimate	8.68

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	6-1 Month Momentum %	-7.43
	12-1 Month Momentum %	-7.43

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.8
	Quick Ratio	0.68
	Cash Ratio	0.22
	Days Inventory	96.79
	Days Sales Outstanding	73.15
	Days Payable	64.77

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.33
	Dividend Payout Ratio	0.65
	3-Year Dividend Growth Rate	5.2
	Forward Dividend Yield %	3.44
	5-Year Yield-on-Cost %	4.57
	Shareholder Yield %	2.99

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	70.68
	Operating Margin %	33.18
	Net Margin %	5.79
	EBITDA Margin %	26.94
	FCF Margin %	31.77
	OCF Margin %	33.75
	ROE %	Neg. Equity
	ROA %	2.68
	ROIC %	11.24
	3-Year ROIIC %	355.44
	ROC (Joel Greenblatt) %	162.62
	ROCE %	9.32
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	8

GF Value Rank

6/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	125.32
	Forward PE Ratio	14.45
	PE Ratio without NRI	24.96
	Shiller PE Ratio	54.19
	Price-to-Owner-Earnings	50.45
	PS Ratio	7.18
	Price-to-Free-Cash-Flow	22.57
	Price-to-Operating-Cash-Flow	21.25
	EV-to-EBIT	57.73
	EV-to-Forward-EBIT	20.22
	EV-to-EBITDA	30.32
	EV-to-Forward-EBITDA	15.76
	EV-to-Revenue	8.17
	EV-to-Forward-Revenue	7.62
	EV-to-FCF	25.67
	Price-to-GF-Value	1.2
	Price-to-Projected-FCF	2.49
	Price-to-Median-PS-Value	1.59
	Earnings Yield (Greenblatt) %	1.73
	FCF Yield %	4.45
	Forward Rate of Return (Yacktman) %	-2.04

GF Value™: €147.37

XBUL:4AB

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with 4AB. Try a 7-Day Free Trial to check it out.

AbbVie Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

AbbVie Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-30 08:00	In 106 days
Third quarter earnings results for 2026	2026-10-30	In 105 days
Second quarter earnings conference call for 2026	2026-07-31 08:00	In 15 days
Second quarter earnings results for 2026	2026-07-31	In 14 days
USD 1.730000 Cash Dividend	2026-07-15	176.40 (+0.00%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 09:40	176.40 (+0.00%)
Bank of America Securities Healthcare Conference	2026-05-13 13:20	176.40 (+0.00%)
General meeting for 2026	2026-05-08 09:00	176.40 (+0.00%)
First quarter earnings conference call for 2026	2026-04-29 08:00	176.40 (+0.00%)
First quarter earnings results for 2026	2026-04-29	176.40 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adu	2026-07-17
	SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development	2026-07-14
	AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma	2026-07-06
	AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma	2026-06-29
	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata	2026-06-29
	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo	2026-06-29
	SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease	2026-06-26
	AbbVie to Host Second-Quarter 2026 Earnings Conference Call	2026-06-26
	BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026	2026-06-24
	Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patien	2026-06-23

10/Page

Articles on AbbVie Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.